Anesthesia Pharmacology: Diabetes Management Practice Questions
Return
Click on the correct answer.
Repaglinide (Pandin) is an oral insulin releasing agent belonging to the sulfonylurea class.
? True ? FalseRepaglinide (Pandin):
? Mechanism of action: stimulates insulin release in pancreatic
ß cells by closing K+ ATP potassium channels. ? Exhibits complete absorption following oral administration. ? Both ? NeitherRepaglinide (re PAG li nide) (Pandin):
? Following repaglinide-mediated ATP-dependent potassium channel blockade, the cell membrane is depolarized and calcium entry is facilitated. ? Exhibits an elimination half-life of about an hour ? Both ? NeitherRepaglinide is minimally metabolized and excreted as parent compound in the urine.
? True ? FalseRepaglinide (Prandin):
? Resembes glyburide ? Undergoes hepatic metabolism yielding a range of biologically active metabolites. ? Both ? NeitherRepaglinide administration is associated with a brief, rapid insulin pulse.
? True ? FalseRepaglinide can be used in combination with metformin.
? True ? FalseRepaglinide:
? Principal side effect is hypoglycemia. ? Repaglinide administration may exhibit secondary failure (a reduced drug efficacy) following initial enhanced glycemic control. ? Both ? NeitherRepaglinide metabolism is associated with:
? Liver ? Kidney ? Both ? NeitherRepaglinide should be administered cautiously with attention paid to dosing in patients exhibiting renal insufficiency.
? True ? FalsePotentiation of the action of repaglinide:
? May occur due to concurrent administration of drugs that displace repaglinide from plasma protein-binding locations. ? May occur due to concurrent administration of drugs which alter repaglinide metabolism by cytochrome P450 isoforms ? Both ? NeitherPrincipal labeled clinical indication for repaglinide administration: improvement of blood glucose levels in adults with type II diabetes mellitus.
? True ? FalseIn comparing repaglinide to glyburide,a long-duration sulfonylurea drug, repaglinide may be associated with less hypoglycemia.
? True ? FalseRepaglinide administration may be associated with weight gain.
? True ? False
Return
Source Material:
Powers A D'Alessio D Chapters 47:
Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and
Hypoglycemia in Goodman & Gilman's: The Pharmcological
Basis of Therapeutics, 13e, (Brunto LL Hilal-Dandan R Knollmann
BC, eds) McGraw-Hill Education, 2018 .
Masharani U Diabetes
Mellitus (27-01) in Current Medical Diagnosis & Treatment (Papadakis
MA McPhee SJ Rabow MW McQuaid KR, eds) 61e McGraw Hill 2022.
Drugs (Access
Medicine)